Company Description
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients.
The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.
The company’s pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28.
It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program.
The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 4, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | John Celebi |
Contact Details
Address: 1405 Research Boulevard, Suite 125 Rockville, Maryland 20850 United States | |
| Phone | 240 243 8000 |
| Website | senseibio.com |
Stock Details
| Ticker Symbol | SNSE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001829802 |
| CUSIP Number | 81728A108 |
| ISIN Number | US81728A1088 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John K. Celebi M.B.A. | President, Chief Executive Officer and Director |
| Dr. Edward Van der Horst Ph.D. | Chief Scientific Officer |
| Stephanie Krebs M.B.A., M.S. | Chief Business Officer |
| Josiah Craver | Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer |
| Lora Pike | Vice President of Investor Relations and Communications |
| Christopher W. Gerry J.D. | Senior Vice President, General Counsel and Secretary |
| Dr. Aaron Weitzman FACP, M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 9, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |
| May 23, 2025 | 8-K | Current Report |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 11, 2025 | ARS | Filing |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |